


## Avotaciclib trihydrochloride

<b>Cat. No.:</b>	HY-137432A
<b>CAS No.:</b>	1983984-01-5
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>14</sub> Cl <sub>3</sub> N <sub>7</sub> O
<b>Molecular Weight:</b>	390.66
<b>Target:</b>	CDK
<b>Pathway:</b>	Cell Cycle/DNA Damage
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 5 mg/mL (12.80 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.5598 mL	12.7989 mL	25.5977 mL
	5 mM	0.5120 mL	2.5598 mL	5.1195 mL
	10 mM	0.2560 mL	1.2799 mL	2.5598 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

CDK1

### REFERENCES

[1]. Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA